10q10k10q10k.net
Gossamer Bio, Inc.

Gossamer Bio, Inc.GOSSEarnings & Financial Report

Nasdaq · Health Care · Pharmaceutical Preparations

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics for patients with serious immunology, inflammation and oncology conditions. It advances a pipeline of proprietary product candidates across multiple clinical phases, primarily serving healthcare markets in North America and other global regions.

Q4 2025Q3 2025Q2 2024Q1 2024Q3 2023Q2 2023

Revenue

$0

Gross Profit

N/A

Operating Profit

$-46.3M

Net Profit

$-42.5M

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

YoY Growth

N/A

EPS

$-0.45

Gossamer Bio, Inc. Q2 FY2023 Financial Summary

Gossamer Bio, Inc. reported revenue of $0 for Q2 FY2023, with a net profit of $-42.5M (up 24.7% YoY) (N/A margin).

Key Financial Metrics

Total Revenue$0
Net Profit$-42.5M
Gross MarginN/A
Operating MarginN/A
Report PeriodQ2 FY2023

Gossamer Bio, Inc. Quarterly Revenue & Net Profit History

Gossamer Bio, Inc. results over the last 6 reported quarters, including revenue, net profit and year-over-year growth.

QuarterRevenueRevenue YoYNet ProfitNet Margin
Q4 FY2025$13.8M+47.1%$-47.2M-342.3%
Q3 FY2025$13.3M+40.2%$-48.2M-362.7%
Q2 FY2024$95.8M—$49.2M51.4%
Q1 FY2024$0—$-41.9MN/A
Q3 FY2023$0—$-40.0MN/A
Q2 FY2023$0—$-42.5MN/A

Income Statement

Q2 2023Q3 2023Q1 2024Q2 2024Q3 2025Q4 2025
Revenue$0$0$0$95.8M$13.3M$13.8M
YoY GrowthN/AN/AN/AN/A40.2%47.1%

Balance Sheet

Q2 2023Q3 2023Q1 2024Q2 2024Q3 2025Q4 2025
Assets$181.7M$347.9M$259.4M$373.4M$208.8M$172.2M
Liabilities$244.5M$243.3M$232.6M$291.9M$291.2M$295.0M
Equity$-62.8M$104.6M$26.7M$81.5M$-82.3M$-122.8M

Cash Flow

Q2 2023Q3 2023Q1 2024Q2 2024Q3 2025Q4 2025
Operating CF$-38.3M$-34.5M$-52.3M$116.3M$-36.2M$-48.3M